---
title: "Tianjin Development: Lishengpharma's mid-term net profit attributable to the parent company is 343 million yuan, an increase of 235.04% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254094917.md"
description: "According to the Zhitong Finance APP, Tianjin Development announced the performance of its indirectly non-wholly-owned subsidiary Tianjin Lishengpharma Co., Ltd. (Lishengpharma) for the six months ending June 30, 2025, with total operating revenue of RMB 732 million, a year-on-year decrease of 1.76%; net profit attributable to the owners of the parent company of RMB 343 million, a year-on-year increase of 235.04%; and basic earnings per share of RMB 1.33"
datetime: "2025-08-22T04:28:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254094917.md)
  - [en](https://longbridge.com/en/news/254094917.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254094917.md)
generator: "portal-rs"
---

# Tianjin Development: Lishengpharma's mid-term net profit attributable to the parent company is 343 million yuan, an increase of 235.04% year-on-year

According to the Zhitong Finance APP, Tianjin Development (00882) announced the performance of its indirectly non-wholly-owned subsidiary Tianjin Lishengpharma Co., Ltd. (Lishengpharma) for the six months ending June 30, 2025, with total operating revenue of RMB 732 million, a year-on-year decrease of 1.76%; net profit attributable to the owners of the parent company of RMB 343 million, a year-on-year increase of 235.04%; and basic earnings per share of RMB 1.33

### Related Stocks

- [002393.CN](https://longbridge.com/en/quote/002393.CN.md)

## Related News & Research

- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [CoTec-backed MagIron reports strong results from independent DR-grade iron pellet tests](https://longbridge.com/en/news/296478902.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)
- [Earth Science Tech (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy](https://longbridge.com/en/news/296513181.md)
- [Tai Hing Group Holdings (SEHK:6811) Stock Price Tracks Profit Rebound Against Thin Margins](https://longbridge.com/en/news/296688951.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**